{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:38:28Z","timestamp":1792442308242,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":2261,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1093\/annonc\/mdt177","type":"journal-article","created":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T02:13:20Z","timestamp":1368670400000},"page":"2256-2261","source":"Crossref","is-referenced-by-count":32,"title":["Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy"],"prefix":"10.1016","volume":"24","author":[{"given":"R.","family":"Kurzrock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Busaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt177_bb0010","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/hmg\/3.10.1895","article-title":"RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer","volume":"3","author":"Blaugrund","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1093\/annonc\/mdt177_bb0015","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archinte.1985.00360070126021","article-title":"Early diagnosis and treatment of medullary thyroid carcinoma","volume":"145","author":"Wells","year":"1985","journal-title":"Arch Intern Med"},{"key":"10.1093\/annonc\/mdt177_bb0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1040-8428(85)80008-1","article-title":"CEA-related antigens: molecular biology and clinical significance","volume":"2","author":"Shively","year":"1985","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdt177_bb0025","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1158\/1078-0432.CCR-09-0786","article-title":"Targeting RET receptor tyrosine kinase activation in cancer","volume":"16","author":"Phay","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt177_bb0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt177_bb0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assn"},{"key":"10.1093\/annonc\/mdt177_bb0040","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1210\/jcem.85.2.6556","article-title":"Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC)","volume":"85","author":"Cohen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdt177_bb0045","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1158\/1078-0432.CCR-09-1241","article-title":"Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies","volume":"15","author":"Hong","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt177_bb0050","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt177_bb0055","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/0008-5472.CAN-06-4605","article-title":"The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells","volume":"67","author":"Akeno-Stuart","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdt177_bb0060","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/1097-0142(19840115)53:2<278::AID-CNCR2820530216>3.0.CO;2-Z","article-title":"Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma","volume":"53","author":"Busnardo","year":"1984","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt177_bb0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jjco\/hyf011","article-title":"Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma","volume":"32","author":"Ito","year":"2002","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdt177_bb0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/172460089400900104","article-title":"Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma","volume":"9","author":"Fugazzola","year":"1994","journal-title":"Int J Biol Markers"},{"key":"10.1093\/annonc\/mdt177_bb0075","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1200\/JCO.2006.07.3411","article-title":"We should desist using RECIST, at least in GIST","volume":"25","author":"Benjamin","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt177_bb0080","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt177_bb0085","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt177_bb0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpendmet0717","article-title":"New therapeutic approaches to treat medullary thyroid carcinoma","volume":"4","author":"Schlumberger","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1093\/annonc\/mdt177_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00264621","article-title":"Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer","volume":"16","author":"Mannini","year":"1988","journal-title":"Urol Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419369261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419369261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/9\/2256\/518279\/mdt177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:42:09Z","timestamp":1624693329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419369261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0923753419369261"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt177","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}